Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 15/20 | 0.36 |
| ▸ | ABL1 | P00519 | 9/20 | 0.35 |
| ▸ | ABL2 | P42684 | 9/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.34 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22684474 | 0.89 | PRMT5 (0.33) | — | |
| SCHEMBL22683366 | 0.87 | EPHA2 (0.36) | EGFREPHA2EPHB4KDRERBB2 | |
| SCHEMBL23892504 | 0.82 | SRC (0.41) | SRCABL1ABL2EGFREPHA2 | |
| SCHEMBL23892412 | 0.80 | PRMT5 (0.41) | SRCABL1ABL2 | |
| SCHEMBL22002269 | 0.80 | SRC (0.36) | SRCABL1ABL2EGFRERBB2 | |
| SCHEMBL22002059 | 0.78 | PRMT5 (0.39) | — | |
| SCHEMBL18571891 | 0.78 | SRC (0.39) | SRCABL1ABL2EGFRERBB2 | |
| SCHEMBL22685136 | 0.77 | PRMT5 (0.38) | — | |
| SCHEMBL22684795 | 0.76 | PRMT5 (0.37) | — | |
| SCHEMBL22002115 | 0.76 | PRMT5 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2022-05-03 | — | — | US | disclosed |
| US-20200360416-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11318157-B2 | 6-6 bicyclic aromatic ring substituted nucleoside analogues for use as PRMT5 inhibitors | PRMT5, PRMT6, PRMT1 | SRC 1585/4885ABL1 655/4885ABL2 2288/4885 |
| US-20200360416-A1 | NOVEL 6-6 BICYCLIC AROMATIC RING SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | PRMT5, PRMT6, PRMT1 | SRC 2130/4885ABL1 1007/4885ABL2 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.